Skip to main content
SpringerLink
Log in

Antihypertonika

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2020

  • 2979 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Agarwal R (2017) Implications of blood pressure measurement technique for implementation of systolic blood pressure intervention trial (SPRINT). J Am Heart Assoc 6:e4536. https://doi.org/10.1161/JAHA.116.004536

    Article  Google Scholar 

  • Anlauf M (2013) Individualisierte Entscheidungen bei der Behandlung der Hypertonie. Arzneiverordn Prax 40:2–4

    Google Scholar 

  • Anlauf M, Weber F (2005) Bedeutung der Therapie mit Antihypertensiva für die kardiovaskuläre Prävention. In: Bundesärztekammer Berlin (Hrsg) Fortschritt und Fortbildung in der Medizin, Bd. 29. Deutscher Ärzte-Verlag, Köln

    Google Scholar 

  • Anlauf M, Weber F (2018a) Antihypertonika. In: Schwabe U et al (Hrsg) Arzneiverordnungsreport 2018. Springer, Berlin Heidelberg, S 394

    Google Scholar 

  • Anlauf M, Weber F (2018b) Blutdruckmessungen zur Hochdruckbekämpfung sollten i. d. R. mit Automaten erfolgen. Dtsch Med Wochenschr 143:59–60

    PubMed  Google Scholar 

  • Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, ACCF Task Force (2011) ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 123:2434–2506

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2019) Hydrochlorothiazid: Risiko von nichtmelanozytärem Hautkrebs – Empfehlungen der AkdÄ zur Behandlung von Hypertonie und Herzinsuffizienz. Arzneiverordnung in der Praxis 46, Bd. 1–2

    Google Scholar 

  • Azizi M, Rossignol P, Hulot JS (2019) Emerging Drug Classes and Their Potential Use in Hypertension. Hypertension 74:1075–1083

    CAS  Google Scholar 

  • Barnes H, Brown Z, Burns A, Williams T (2019) Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev 1:CD12621

    PubMed  Google Scholar 

  • Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898

    CAS  PubMed  Google Scholar 

  • Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher A, Bulpitt C, HYVET Study Group (2011) Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344:d7541

    CAS  PubMed  Google Scholar 

  • Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393–1401

    CAS  PubMed  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356:1955–1964

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2014) Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384:591–598

    Google Scholar 

  • Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C, Lee DP, Ma A, Ewen S, Cohen DL, Wilensky R, Devireddy CM, Lea J, Schmid A, Weil J, Agdirlioglu T, Reedus D, Jefferson BK, Reyes D, D’Souza R, Sharp ASP, Sharif F, Fahy M, DeBruin V, Cohen SA, Brar S, Townsend RR, SPYRAL HTN-OFF MED Pivotal Investigators (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): A multicentre, randomised, sham-controlled trial. Lancet 395:1444–1451

    PubMed  Google Scholar 

  • Brown MJ (2011) Personalised medicine for hypertension. BMJ 343:d4697

    PubMed  Google Scholar 

  • Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM, British Hypertension Society’s Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group (2016) Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 4:136–147

    CAS  PubMed  PubMed Central  Google Scholar 

  • Byrne C, Pareek M, Vaduganathan M, Biering-Sørensen T, Qamar A, Pandey A, Olesen TB, Olsen MH, Bhatt DL (2019) Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvz050

    Article  PubMed  Google Scholar 

  • Canadian Hypertension https://guidelines.hypertension.ca/prevention-treatment/uncomplicated-hypertension-goals-of-therapy/. Zugegriffen: 23. Mai 2020

  • Chow CK, Thakkar Z, Bennett A, Hillis G, Burke M, Usherwood T, Vo K, Rogers K, Atkins E, Webster R, Chou M, Dehbi HM, Salam A, Patel A, Neal B, Peiris D, Krum H, Chalmers J, Nelson M, Reid CM, Woodward M, Hilmer S, Thom S, Rodgers A (2017) Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet 389:1035–1042

    CAS  PubMed  Google Scholar 

  • Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, MOXCON Investigators (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure. Eur J Heart Fail 5:659–667

    CAS  PubMed  Google Scholar 

  • Dahlöf B, Sever PS, Neil R, Poulter NP, Wedel H (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:895–906

    PubMed  Google Scholar 

  • Davis BR, Piller LB, Cutler JA, Furberg CC, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group (2006) Role of diuretics in the prevention of heart failure. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 113:2201–2210

    CAS  PubMed  Google Scholar 

  • Desch S, Okon T, Heinemann D, Kulle K, Kulle K, Röhnert K, Sonnabend M, Petzold M, Müller U, Schuler G, Eitel I, Thiele H, Lurz P (2015) Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 65:1202–1208

    CAS  Google Scholar 

  • Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS (2012) Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 59:1124–1131

    CAS  PubMed  PubMed Central  Google Scholar 

  • Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201–207

    CAS  PubMed  Google Scholar 

  • Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957–967

    Google Scholar 

  • Falaschetti E, Mindell J, Knott C, Poulter N (2014) Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383:1912–1919

    PubMed  Google Scholar 

  • Hermida RC, Crespo JJ, Domínguez-Sardiña M, Otero A, Moyá A, Ríos MT, Sineiro E, Castiñeira MC, Callejas PA, Pousa L, Salgado JL, Durán C, Sánchez JJ, Fernández JR, Mojón A, Ayala DE, Hygia Project Investigators (2019) Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz754

    Article  PubMed  Google Scholar 

  • Ho CLB, Breslin M, Doust J, Reid CM, Nelson MR (2018) Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood Pressure Study. BMJ Open 8(3):e17723. https://doi.org/10.1136/bmjopen-2017-017723

    Article  Google Scholar 

  • Hopkins W, Rubin LJ (2020) Treatment of pulmonary hypertension in adults. https://www.uptodate.com/contents/treatment-of-pulmonary-hypertension-in-adults

  • Jamerson K, Weber MA, Bakris GL, Dahlöf B, Jamerson K, Weber MA, Bakris GL, Dahlöf B (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417–2428

    CAS  PubMed  Google Scholar 

  • James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507–520

    CAS  PubMed  Google Scholar 

  • Khan NA, Rabkin SW, Zhao Y et al (2018) Effect of lowering diastolic pressure in patients with and without cardiovascular disease: analysis of the SPRINT (systolic blood pressure intervention trial). Hypertension 71:840–847

    CAS  PubMed  Google Scholar 

  • Kintscher U, Böhm M, Goss F, Kolloch R, Kreutz R, Schmieder R, Schunkert H (2014) Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. Kardiologie 8:223–230

    CAS  Google Scholar 

  • Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, SHEP Collaborative Research Group (2005) Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95:29–35

    CAS  PubMed  Google Scholar 

  • Krieger EM, Drager LF, Giorgi DMA et al (2018) Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension 71:681–690

    CAS  PubMed  Google Scholar 

  • Lindholm LH, Carlberg B, Samuelsson O (2005) Should betablockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545–1553

    Google Scholar 

  • Malik AH, Shetty S, Kar K, Accaoui RE (2019) Effect of β-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis. J Geriatr Cardiol 16(3):291–297

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mancia G, Corrao G (2018) Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From Italy. Circulation 137:889–890

    PubMed  Google Scholar 

  • Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Chairpersons and Section Coordinators of the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH), European Society of Cardiology (ESC) (2014) Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. J Hypertens 32:1551–1552

    CAS  PubMed  Google Scholar 

  • Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O (2017) Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial. Chest 151:106–118

    PubMed  Google Scholar 

  • Middeke M, Lemmer B, Kreutz R, Schrader J, Holzgreve H (2020) Antihypertensiva nicht generell abends nehmen. MMW Fortschr Med 162:34–36

    PubMed  Google Scholar 

  • National Institute for Health and Care Excellence (2019) Hypertension in adults: diagnosis and management. https://www.nice.org.uk/guidance/ng136/chapter/Recommendations#starting-antihypertensive-drug-treatment. Zugegriffen: 23. Mai 2020

  • Neuhauser H, Diederichs C, Boeing H, Felix SB, Jünger C, Lorbeer R, Meisinger C, Peters A, Völzke H, Weikert C, Wild P, Dörr M (2016) Bluthochdruck in Deutschland – Daten aus sieben bevölkerungsbasierten epidemiologischen Studien (1994–2012). Dtsch Arztebl Int 113:809–815

    PubMed  PubMed Central  Google Scholar 

  • Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, Godbole AV, Kshirsagar PP, Agarwal MA, Sharma KH, Mathur SL, Kumbla MM (2016) Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 67:379–389

    CAS  PubMed  Google Scholar 

  • Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, SERAPHIN Investigators (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809–818

    CAS  PubMed  Google Scholar 

  • Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H (2014) Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 383:1899–1911

    PubMed  PubMed Central  Google Scholar 

  • Rothwell PM, Coull AJ, Silver LE et al (2005) Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366:1773–1783

    CAS  PubMed  Google Scholar 

  • Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR (2010a) Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375:895–905

    PubMed  Google Scholar 

  • Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS, ASCOT-BPLA and MRC Trial Investigators (2010b) Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9:469–480

    CAS  PubMed  Google Scholar 

  • Roush GC, Holford TR, Guddati AK (2012) Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 59:1110–1117

    CAS  PubMed  Google Scholar 

  • Salam A, Atkins ER, Hsu B, Webster R, Patel A, Rodgers A (2019) Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 37:1567–1573

    CAS  PubMed  Google Scholar 

  • Sexton DJ, Canney M, O’Connell MDL, Moore P, Little MA, O’Seaghdha CM, Kenny RA (2017) Injurious falls and syncope in older community-dwelling adults meeting inclusion criteria for SPRINT. JAMA Intern Med 177:1385–1387

    PubMed  PubMed Central  Google Scholar 

  • Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Hobbs FDR, McManus RJ (2018) Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern Med 178:1626–1634

    PubMed  PubMed Central  Google Scholar 

  • Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ (2014) Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 64:588–597

    PubMed  PubMed Central  Google Scholar 

  • Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G (2018) Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: data from the randomized SERAPHIN trial. PLoS ONE 13(3):e193226. https://doi.org/10.1371/journal.pone.0193226

    Article  CAS  Google Scholar 

  • Staessen JA, Birkenhäger WH (2005) Evidence that new antihypertensives are superior to older drugs. Lancet 366:869–871

    PubMed  Google Scholar 

  • Staessen JA, Gasowski J, Wang Lj G, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH (2000) Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355:865–872

    Google Scholar 

  • Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB (2019) Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 394:1816–1826

    PubMed  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288:2981–2997

    Google Scholar 

  • The SPRINT Research Group (2015) A randomized trial of intensive versus standard blood pressure control. N Engl J Med 373:2103–2116

    PubMed Central  Google Scholar 

  • The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH), The European Society of Cardiology (ESC) (2018) 2018 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 36:1953–2041

    Google Scholar 

  • Thomopoulosa C, Paratib G, Zanchettid A (2017) Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overviewand meta-analyses of randomized trials. J Hypertens 35:2138–2149

    Google Scholar 

  • Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T (2018) Risk of all-cause mortality in diabetic patients taking beta-blockers. Mayo Clin Proc 93:409–418

    CAS  PubMed  Google Scholar 

  • Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C (2004) Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43:963–969

    CAS  PubMed  Google Scholar 

  • Vidal-Petiot E, Greenlaw N, Ford I et al (2018) Relationships between components of blood pressure and cardiovascular events in patients with stable coronary artery disease and hypertension. Hypertension 71:168–176

    CAS  PubMed  Google Scholar 

  • Weber F, Anlauf M (2014) Treatment resistant hypertension – investigation and conservative management. Dtsch Arztebl Int 111:425–431

    PubMed  PubMed Central  Google Scholar 

  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison-Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:e13–e115

    CAS  Google Scholar 

  • Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, British Hypertension Society Studies Group (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059–2068

    CAS  PubMed  PubMed Central  Google Scholar 

  • Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ, British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group (2018) Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 6:464–475

    PubMed  PubMed Central  Google Scholar 

  • Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM, SPRINT Research Group (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: A randomized clinical trial. JAMA 315:2673–2682

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wiysonge CS, Opie LH (2013) β-Blockers as initial therapy for hypertension. JAMA 310:1851–1852

    CAS  PubMed  Google Scholar 

  • Yano Y, Stamler J, Garside DB, Daviglus ML, Franklin SS, Carnethon MR, Liu K, Greenland P, Lloyd-Jones DM (2015) Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol 65:327–335

    PubMed  PubMed Central  Google Scholar 

  • Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR (1999) Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 126:1522–1530

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Plettke-Weg 12, 27570, Bremerhaven, Deutschland

    Prof. Dr. med. Manfred Anlauf

  2. Thiemannstraße 18, 45219, Essen, Deutschland

    Prof. Dr. med. Franz Weber

Authors
  1. Prof. Dr. med. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Franz Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred Anlauf .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Arzneimittelkommission der deutschen Ärzteschaft, Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Der/die Herausgeber bzw. der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Anlauf, M., Weber, F. (2020). Antihypertonika. In: Schwabe, U., Ludwig, WD. (eds) Arzneiverordnungs-Report 2020. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62168-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62168-4_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62167-7

  • Online ISBN: 978-3-662-62168-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation